Active ingredientRemogliflozinCat. No. P-R033-001CAS 329045-45-6Family · Pharmaceutical analytical standards
Remogliflozin
An SGLT2 transporter inhibitor (gliflozin) for type 2 diabetes, discovered in Japan and first marketed in India in 2019. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Unlike most gliflozins, which are C-glucosides, it is an O-glucoside, more vulnerable to intestinal enzymes: this is why it is taken as a prodrug, remogliflozin etabonate.
Go to the active ingredient →Active ingredientRemogliflozinCat. No. P-R033-001CAS 329045-45-6
Isotopically labelledRemogliflozin Etabonate-d7Cat. No. P-R033-002
Isotopically labelledRemogliflozin-d7Cat. No. P-R033-003
ImpurityRemogliflozin EtabonateCat. No. P-R033-004CAS 442201-24-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.